

**Question for written answer E-002695/2024
to the Commission**
Rule 144
Leire Pajín (S&D)

Subject: Competition among protein-based COVID-19 vaccines

Member States are promoting seasonal vaccination campaigns against COVID-19 in an effort to prevent the spread of the virus. Those campaigns are geared mainly towards the most vulnerable, such as healthcare workers, the elderly and people with immunodeficiency.

The EMA has authorised a broad range of messenger RNA vaccines. However, for protein-based vaccines, in the context of the update for the 2024 campaign, only one model has obtained approval.

Bearing in mind that the availability of and access to a larger supply of vaccines has a direct impact on the optimisation of public resources and provides greater coverage among the general population:

1. What view does the Commission take of the paucity of competition in protein-based vaccines for the 2024 campaign?
2. Is the Commission considering backing the availability of more protein-based vaccines for forthcoming COVID-19 vaccination campaigns?

Submitted: 27.11.2024